ARNA - Earnings announcements

– Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021. Key Program & Corporate Updates In December announced that Pfizer Inc. and Arena entered into a definitive agreement under which Pfizer has agreed to acquire Arena In November achieved target enrollment for Study A in the Phase 2/3 CULTIVATE trial for etrasimod in Crohn's disease In November the first participant was randomized in the Phase 2 trial for temanogrel in Raynaud's phenomenon secondary to systemic sclerosis Phase 3 ELEVATE program

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will release its fourth quarter and full-year 2021 financial results and provide a corporate update on Wednesday, February 23, 2022, after the close of the U.S. financial markets. About Arena Pharmaceuticals ARENA Pharmaceuticals is a team with a singular purpose – deliver important medicines to patients. In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get medicines to patients, and relentlessly execute until it's done. ARENA - Care More. Act Differently. Forward-Looking Statements Certain statements in this press relea

Proposed acquisition offers potentially new, differentiated best-in-class approach to address unmet need for a broader number of patients with immuno-inflammatory diseases Expands innovative pipeline potentially enhancing growth through 2025 and beyond Transaction valued at $100 per Arena share in cash, for a total equity value of approximately $6.7 billion Pfizer to host analyst and investor call at 10am EST today with Pfizer I&I executives Pfizer Inc. (NYSE:PFE) and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapie

–  Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout –  First participant randomized in the Phase 2 trial for temanogrel in Raynaud's phenomenon secondary to systemic sclerosis –  Strong liquidity position to support continued pipeline progress Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2021. "During the quarter, the team continued to make significant progress across all key programs, including reaching full enrollment for the ELEVATE UC 12 program," said Amit D. Munshi, President and CEO of Arena. "ELEVATE UC 12 and ELEVATE UC 52 remain on track and we continu

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will release its third quarter 2021 financial results and provide a corporate update on Thursday, November 4, 2021, after the close of the U.S. financial markets. The Company will host a question and answer session via conference call and live webcast with the investment community the same day at 4:30 PM ET. Conference Call & Webcast Information When: Thursday, November 4, 2021, at 4:30 PM ET Webcast: Conference call will be broadcast live in listen-only mode on the company's investor relations website at https://invest.arenapharm.com/events-presentations A recording of the conference call will be archived for 30 days after the call. About Arena

– Phase 3 ELEVATE UC 12 trial reached full enrollment; topline data expected Q1 2022 with ELEVATE UC 52 – Liquidity position at ~$1.0 billion as of June 30, 2021 to support continued pipeline progress Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the second quarter ended June 30, 2021. "With today's announcement of the ELEVATE UC 12 trial reaching full enrollment, we look forward to a potentially transformational data readout of ELEVATE UC 12 and ELEVATE UC 52 in the first quarter of next year. We are also pleased with our recently announced partnership with Aristea to strengthen our mid-stage immunology pipeline," said Ami

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will release its second quarter 2021 financial results and provide a corporate update on Thursday, August 5, 2021, after the close of the U.S. financial markets. The Company will host a live webcast to discuss the results with the investment community the same day at 4:30 PM ET. Conference Call & Webcast Information When: Thursday, August 5, 2021, at 4:30 PM ET Webcast: Conference call will be broadcast live in listen-only mode on the company's investor relations website at https://invest.arenapharm.com/events-presentations. A recording of the conference call will be archived for 30 days after the call. About Arena Pharmaceuticals ARENA Pharmac

Agreement Provides Arena with Exclusive Option to Acquire Aristea and its CXCR2 Programs post-Phase 2 Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Aristea Therapeutics, Inc. today announced a strategic collaboration to advance the clinical development of RIST4721, an oral CXCR2 antagonist being developed by Aristea for the treatment of palmoplantar pustulosis (PPP) and other neutrophil-mediated diseases. Under the terms of the agreement, Arena will provide a $60 million upfront payment to Aristea and a $10 million equity investment in Aristea's Series B financing. In return, Aristea has granted Arena an exclusive option to acquire Aristea, including rights to all CXCR2 programs, upon com